Bremelanotide
Bremelanotide is tracked as part of the peptide, metabolic, mitochondrial, NAD, or longevity research landscape, with claims separated by evidence type and product documentation.
Independent research database
A plain-language research repository for peptides, NAD+ compounds, GLP-1 context, metabolic medicines, recovery, skin, sleep, and longevity claims. Start with what was actually studied before trusting a headline, supplier page, or protocol.
Evidence limits, safety context, COA review, supplier transparency, and commercial disclosure stay visible.
Platform snapshot
Selected records
Each record separates identity, proposed mechanisms, research stage, safety context, testing documents, and commercial information.
Bremelanotide is tracked as part of the peptide, metabolic, mitochondrial, NAD, or longevity research landscape, with claims separated by evidence type and product documentation.
A GLP-1 receptor agonist with controlled clinical evidence for specific approved uses, where product status, jurisdiction, and formulation matter.
Tesamorelin is tracked as part of the peptide, metabolic, mitochondrial, NAD, or longevity research landscape, with claims separated by evidence type and product documentation.
A dual GIP/GLP-1 receptor agonist with strong clinical evidence in approved-product contexts and separate questions for compounded products.
Creatine is tracked as part of the peptide, metabolic, mitochondrial, NAD, or longevity research landscape, with claims separated by evidence type and product documentation.
Elamipretide is tracked as part of the peptide, metabolic, mitochondrial, NAD, or longevity research landscape, with claims separated by evidence type and product documentation.
Tools
Use the live compound index now. More tools will unlock only when their canonical data and workflows are ready.
Filter the public compound index by name, alias, class or research topic.
Search →Only confirmed, source-backed relationships are published here.
Only confirmed, source-backed relationships are published here.
Only confirmed, source-backed relationships are published here.
Coverage and method
Every public record passes through a documented pipeline that separates source material, canonical facts and editorial context.
Read the methodologyIn development
Early access is planned for alerts, watchlists, expanded history and advanced supplier intelligence. Membership is not yet open.
Peptide Record
Research evidence, supplier observations and commercial relationships remain separate. Uncertainty and dataset limits stay visible.
Read the methodology →